Amptron’s R &D is based out of the US and this will enable Max to obtain US and other global certifications. Max will retain the right to market, sell and distribute the products in India.
It is the first-ever approval in India for the treatment of Female Pattern Hair Loss (FPHL) and will be available only on prescription by a dermatologist
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
The DGTR has recommended US $ 3.2 per kg and US $ 3.55 per kg duty on imports
Marketed under the brand name DGJAJ, it helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
The focus is on wellness and personal care products
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The newest entrant from the company is the MOSS 1800F with an oxygen flow rate of 180 LPM or 10.8 Nm3/hour
Subscribe To Our Newsletter & Stay Updated
